Circulation Research 2000-11-24

Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Z Yu, F Xu, L M Huse, C Morisseau, A J Draper, J W Newman, C Parker, L Graham, M M Engler, B D Hammock, D C Zeldin, D L Kroetz

Index: Circ. Res. 87(11) , 992-8, (2000)

Full Text: HTML

Abstract

The cytochrome P450-derived epoxyeicosatrienoic acids (EETs) have potent effects on renal vascular reactivity and tubular sodium and water transport; however, the role of these eicosanoids in the pathogenesis of hypertension is controversial. The current study examined the hydrolysis of the EETs to the corresponding dihydroxyeicosatrienoic acids (DHETs) as a mechanism for regulation of EET activity and blood pressure. EET hydrolysis was increased 5- to 54-fold in renal cortical S9 fractions from the spontaneously hypertensive rat (SHR) relative to the normotensive Wistar-Kyoto (WKY) rat. This increase was most significant for the 14,15-EET regioisomer, and there was a clear preference for hydrolysis of 14, 15-EET over the 8,9- and 11,12-EETs. Increased EET hydrolysis was consistent with increased expression of soluble epoxide hydrolase (sEH) in the SHR renal microsomes and cytosol relative to the WKY samples. The urinary excretion of 14,15-DHET was 2.6-fold higher in the SHR than in the WKY rat, confirming increased EET hydrolysis in the SHR in vivo. Blood pressure was decreased 22+/-4 mm Hg (P:<0.01) 6 hours after treatment of SHRs with the selective sEH inhibitor N:, N:'-dicyclohexylurea; this treatment had no effect on blood pressure in the WKY rat. These studies identify sEH as a novel therapeutic target for control of blood pressure. The identification of a potent and selective inhibitor of EET hydrolysis will be invaluable in separating the vascular effects of the EET and DHET eicosanoids.


Related Compounds

Related Articles:

A dual wavelength-activatable gold nanorod complex for synergistic cancer treatment.

2015-07-28

[Nanoscale 7 , 12096-103, (2015)]

Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.

2014-08-15

[Int. J. Pharm. 470(1-2) , 51-62, (2014)]

Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles.

2014-01-01

[J. Microencapsul. 31(5) , 479-87, (2014)]

Reinvestigation of the reactions of carbodiimides with alkoxycarbonylamino acid symmetrical anhydrides. Isolation of two N-acylureas.

1994-02-01

[Int. J. Pept. Protein Res. 43 , 184, (1994)]

Thermal degradation of amorphous glibenclamide.

2012-01-01

[Eur. J. Pharm. Biopharm. 80(1) , 203-8, (2012)]

More Articles...